Tech Company Financing Transactions

Envisagenics Funding Round

On 6/5/2024, Envisagenics received Series B financing from Bristol Myers Squibb, Empire State Development and Red Cell Partners.

Transaction Overview

Company Name
Announced On
6/5/2024
Transaction Type
Venture Equity
Amount
Unknown
Round
Series B
Proceeds Purpose
The company intends to use the funds to further develop its pipeline of novel preclinical oncology assets with its cloud-based AI drug discovery platform, SpliceCore®, and to scale its commercial offerings.

Company Information

Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
101 Ave. of the Americas 3rd Floor
New York, NY 10013
USA
Email Address
Overview
Envisagenics is a New York City-based a bioinformatics company. Biomedical data might hold the key to finding the cure for currently incurable diseases. Our mission is to reduce the complexity of RNA-seq data into plausible candidates for drug and biomarker development.
Profile
Envisagenics LinkedIn Company Profile
Social Media
Envisagenics Company Twitter Account
Company News
Envisagenics News
Facebook
Envisagenics on Facebook
YouTube
Envisagenics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Maria Pineda
  Maria Pineda LinkedIn Profile  Maria Pineda Twitter Account  Maria Pineda News  Maria Pineda on Facebook
Chief Technical Officer
Martin Akerman
  Martin Akerman LinkedIn Profile  Martin Akerman Twitter Account  Martin Akerman News  Martin Akerman on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/5/2024: Fispoke venture capital transaction
Next: 6/5/2024: Liminal venture capital transaction

 

Share this article

 


News on VC Transactions

We do our best to record every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary